JUST IN: Merck seeks FDA emergency use authorization for molnupiravir, an experimental antiviral pill to treat Covid-19
Merck said Monday it is seeking US Food and Drug Administration emergency use authorization for its experimental antiviral Covid-19 treatment, molnupiravir.
If authorization is granted, the drug, made by Merck and Ridgeback Biotherapeutics, would be the first oral antiviral treatment to fight Covid-19. It comes in capsule form.Merck said it is asking for authorization for the capsules to treat infected adults who are at risk of progressing to severe Covid-19 disease or hospitalization.
"It is very important that this now must go through the usual process of careful examination of the data by the Food and Drug Administration both for effectiveness, but also for safety, because whenever you introduce a new compound, safety is very important," Fauci said, noting that vaccines remain"our best tools against Covid-19" by preventing infection and illness, rather than treating it.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Merck asks US FDA to authorize promising anti-COVID pillWASHINGTON (AP) — Drugmaker Merck asked U.S. regulators Monday to authorize its pill against COVID-19 in what would add an entirely new and easy-to-use weapon to the world's arsenal against the pandemic.
続きを読む »
A Pill to Treat COVID Could Be Just Months AwayAt least three promising antiviral treatments for covid-19 are being tested in clinical trials, with results expected as soon as late fall or winter.
続きを読む »
Some States Limit Monoclonal Antibody Treatment to High-Risk, Unvaccinated PatientsAt least two states are recommending that doctors prioritize the limited supply of monoclonal antibody treatments for high-risk COVID-19 patients, including unvaccinated people who face severe disease.
続きを読む »
New York’s Largest Healthcare Provider Fires 1,400 Employees Who Refused To Get VaccinatedNorthwell terminated more than 20 managers last week for refusing to get immunized against Covid-19.
続きを読む »